eslicarbazepine acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4303	236395-14-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eslicarbazepine acetate zebinix exelief aptiom BIA 2-093 Sep-0002093	Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels. Molecular weight: 296.33 Formula: C17H16N2O3 CLOGP: 1.50 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 72.63 ALOGS: -3.43 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

eslicarbazepine acetate
zebinix
exelief
aptiom
BIA 2-093
Sep-0002093

Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.

Molecular weight: 296.33
Formula: C17H16N2O3
CLOGP: 1.50
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 72.63
ALOGS: -3.43
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
S (Water solubility)	4.20 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.39 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Nov. 8, 2013	FDA	SUNOVION PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	201.62	39.06	77	977	132557	63355411
Hyponatraemia	141.48	39.06	57	997	111843	63376125
Generalised tonic-clonic seizure	78.50	39.06	26	1028	28990	63458978
Inappropriate antidiuretic hormone secretion	46.38	39.06	15	1039	15447	63472521
Partial seizures	41.20	39.06	11	1043	5831	63482137
Mitral valve disease	39.57	39.06	9	1045	2471	63485497
Irritability	39.28	39.06	16	1038	31678	63456290

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	252.09	51.53	89	612	104768	34851462

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	282.44	41.60	111	1338	188723	79554216
Hyponatraemia	131.63	41.60	64	1385	177784	79565155
Generalised tonic-clonic seizure	55.28	41.60	23	1426	43887	79699052
Inappropriate antidiuretic hormone secretion	51.56	41.60	19	1430	26294	79716645

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AF04	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Carboxamide derivatives
FDA PE	N0000008486	Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D061567	Voltage-Gated Sodium Channel Blockers
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000185506	Cytochrome P450 3A4 Inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Partial seizure	indication	29753000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.73	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10702536	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10702536	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10702536	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10675287	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10695354	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	10702536	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	11364247	May 6, 2025	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9763954	Sept. 13, 2028	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9763954	Sept. 13, 2028	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9763954	Sept. 13, 2028	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9763954	Sept. 13, 2028	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES
200MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES
400MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES
600MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES
800MG	APTIOM	SUMITOMO PHARMA AM	N022416	Nov. 8, 2013	RX	TABLET	ORAL	9750747	Aug. 24, 2032	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium channel alpha subunit	Ion channel	P35498 P35499 Q01118 Q14524 Q15858 Q99250 Q9NY46 Q9UI33 Q9UQD0 Q9Y5Y9	SCN1A_HUMAN SCN4A_HUMAN SCN7A_HUMAN SCN5A_HUMAN SCN9A_HUMAN SCN2A_HUMAN SCN3A_HUMAN SCNBA_HUMAN SCN8A_HUMAN SCNAA_HUMAN	BLOCKER				CHEMBL	CHEMBL

External reference:

ID	Source
4033118	VUID
N0000190128	NUI
D09215	KEGG_DRUG
4033116	VANDF
4033118	VANDF
C2725262	UMLSCUI
CHEMBL87992	ChEMBL_ID
DB09119	DRUGBANK_ID
C416835	MESH_SUPPLEMENTAL_RECORD_UI
C571001	MESH_SUPPLEMENTAL_RECORD_UI
BEA68ZVB2K	UNII
179344	PUBCHEM_CID
DB14575	DRUGBANK_ID
1482501	RXNORM
207443	MMSL
29871	MMSL
d07507	MMSL
013276	NDDF
013277	NDDF
697998007	SNOMEDCT_US
700015007	SNOMEDCT_US
715615002	SNOMEDCT_US
C2725260	UMLSCUI
CHEMBL315985	ChEMBL_ID
8403	INN_ID
104746-04-5	SECONDARY_CAS_RN
9881504	PUBCHEM_CID
7350	IUPHAR_LIGAND_ID
S5VXA428R4	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Aptiom	HUMAN PRESCRIPTION DRUG LABEL	1	63402-202	TABLET	200 mg	ORAL	NDA	32 sections
Aptiom	HUMAN PRESCRIPTION DRUG LABEL	1	63402-204	TABLET	400 mg	ORAL	NDA	32 sections
Aptiom	HUMAN PRESCRIPTION DRUG LABEL	1	63402-206	TABLET	600 mg	ORAL	NDA	32 sections
Aptiom	HUMAN PRESCRIPTION DRUG LABEL	1	63402-208	TABLET	800 mg	ORAL	NDA	32 sections